Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.
about
Progress in treatment of ANCA-associated vasculitisCyclophosphamide for multiple sclerosisCyclophosphamide therapy in pediatric multiple sclerosisWegener's granulomatosis: current and upcoming therapiesSystemic Sclerosis and Malignancy: A Review of Current DataRole of immunosuppressive therapy for the treatment of multiple sclerosisCancer incidence in systemic sclerosis: meta-analysis of population-based cohort studiesRare diseases.3: Wegener's granulomatosisTreatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effectsThe safety profile of cyclophosphamide in multiple sclerosis therapy.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis.Small vessel vasculitis of the lungManagement of ANCA-associated vasculitis: Current trends and future prospectsOxazaphosphorines: new therapeutic strategies for an old class of drugs.Hemorrhagic cystitis: A challenge to the urologist.Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.The recognition, diagnosis and management of cerebral vasculitis: a European survey.Cyclophosphamide for the treatment of systemic lupus erythematosus.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Combination therapy in autoimmune disease: vasculitis.The downsides of a major medical advanceClinical management and treatment of vasculitis.Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Variability of the impact of adverse events on physicians' decision makingTesting for antineutrophil cytoplasmic antibodies.Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Current and emerging strategies for the management of sarcoidosis.Lights and shadows of cyclophosphamide in the treatment of multiple sclerosisDifficult treatment issues in sarcoidosis.Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamideTreating rheumatic patients with a malignancy.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with PolyangiitisMalignancy risk in vasculitisAssessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'
P2860
Q21195258-E38158C2-7029-4B87-AA9A-B8978357CC40Q24243160-C84F78FE-583C-49DB-9461-EF4CDD68F8E7Q24630626-F6DA61D3-8CF6-489A-9381-F29CF9EA5BB0Q24804964-C154F288-EFC2-4C15-96B1-CFF70ECED616Q26740318-E8772403-F331-4C81-A7B7-39C890598625Q26827467-1CBB2907-7D67-43C2-A6CD-352BAE5A20AAQ26998770-4BC9A6ED-F911-4586-9206-50B79E624111Q27477902-72D8BD5A-7A6D-4339-873D-D73C182EEB84Q28216546-9C892865-AAC0-411C-A0E3-DCE317BC79D8Q31105891-32B8E07C-A45D-40E2-BA04-1826FEC71194Q33346685-2C870947-4560-4998-A21D-C9F3F19445E9Q33514477-2D79AEBF-8AC6-4E42-A80B-B9922546A7FBQ33521057-4FF389FF-1665-4918-AD55-433A4AFB5795Q33715801-AF7D13AE-4D8B-42FF-9724-A959CCAC003AQ33841384-54707FC0-C8B9-4513-A9D4-700EA17517BEQ33922238-5E0E1839-1A1C-4D4C-A533-DA1A0F948981Q33947599-815764F7-5CE9-4168-820E-8ECAD418CA76Q34113899-A8BF27FA-74D1-4744-8B83-04FC489C818FQ34123974-A45981C4-5FF7-4299-816C-33F9EF86CEABQ34124668-DFF19835-500A-4DD2-848B-9F87FC507DD6Q34137174-BDEA9775-F06C-4D5F-865F-9ED0DD131B43Q34226984-1E913CA7-8563-49F3-AE2C-EBFAEB7A6AEFQ34257903-6C2E3740-1047-4492-A1F5-EE13FA9ABAA0Q34309769-642EF64B-D307-4135-ADB8-18896A4C06E5Q34345029-B6588F78-5A5A-4C4D-B39D-977A1198A286Q34395174-5D04A4F1-DC16-429B-9661-7742789C92BDQ34409273-203271C8-34EF-4D50-986F-86159EA2234FQ34538062-A6B62239-0336-4CE2-ABF1-512793B31497Q34569292-807F3917-1C36-4B21-AC37-D762351C3F0CQ34628409-C221F7D1-90BF-4A1F-9DE8-249F93DCF427Q34636680-089932DE-9E1A-430D-8391-803BB8E1F03FQ34922742-BA23CCF2-1DB5-45A3-9549-89672BB1B330Q35067120-F3066B7C-0DB8-4A21-B50C-39F387E04845Q35553364-966B5A69-7FF6-458E-8538-DE1B8A3ECC54Q35557863-E0BA557F-3A99-49DD-8DD8-CB47A4F8EF82Q35579503-494AEAE1-5655-47F7-A7BD-AE61D358B830Q35606909-6C52F161-9BC9-4358-93D6-84E025FE684BQ35992340-4A6383AD-A341-4155-96BA-79C20178B920Q36059573-B03DF762-3204-4184-87DA-0DAE38B9BC6FQ36073447-396F2A53-3196-4AFE-9550-BBA572C5ECD1
P2860
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մարտին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@ast
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@en
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@nl
type
label
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@ast
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@en
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@nl
prefLabel
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@ast
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@en
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@nl
P2093
P1476
Cyclophosphamide-induced cysti ...... s with Wegener granulomatosis.
@en
P2093
Hallahan CW
Hoffman GS
Linehan WM
Lubensky I
Sneller MC
Talar-Williams C
Walther MM
P304
P356
10.7326/0003-4819-124-5-199603010-00003
P407
P577
1996-03-01T00:00:00Z